These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 31744829)

  • 21. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
    Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
    Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
    Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
    J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
    Front Immunol; 2021; 12():677169. PubMed ID: 34354701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UBA5 inhibition restricts lung adenocarcinoma via blocking macrophage M2 polarization and cisplatin resistance.
    Xu D; Zhang D; Wei W; Zhang C
    Exp Cell Res; 2024 Jul; 440(2):114148. PubMed ID: 38936760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma.
    Wang Q; Tang Z; Li C; Li X; Su C
    Front Immunol; 2023; 14():1297588. PubMed ID: 37954616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined cryoablation and PD-1 inhibitor synergistically enhance antitumor immune responses in Lewis lung adenocarcinoma mice via the PI3K/AKT/mTOR pathway.
    Liu Q; Chen X; Qi M; Li Y; Chen W; Zhang C; Wang J; Han Z; Zhang C
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167262. PubMed ID: 38815768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the ERĪ²/HER Oncogenic Network in
    Almotlak AA; Farooqui M; Soloff AC; Siegfried JM; Stabile LP
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
    Park C; Na KJ; Choi H; Ock CY; Ha S; Kim M; Park S; Keam B; Kim TM; Paeng JC; Park IK; Kang CH; Kim DW; Cheon GJ; Kang KW; Kim YT; Heo DS
    Theranostics; 2020; 10(23):10838-10848. PubMed ID: 32929383
    [No Abstract]   [Full Text] [Related]  

  • 29. Developing an Arrayed CRISPR-Cas9 Co-Culture Screen for Immuno-Oncology Target ID.
    Gee S; Nelson N; Bornot A; Carter N; Cuomo ME; Dovedi SJ; Smith PD; Gianni D; Baker DJ
    SLAS Discov; 2020 Jul; 25(6):581-590. PubMed ID: 32375580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated expression of
    Feng Z; Zhang J; Zheng Y; Wang Q; Min X; Tian T
    Per Med; 2021 Mar; 18(2):115-127. PubMed ID: 33576264
    [No Abstract]   [Full Text] [Related]  

  • 31. The KRAS
    Briere DM; Li S; Calinisan A; Sudhakar N; Aranda R; Hargis L; Peng DH; Deng J; Engstrom LD; Hallin J; Gatto S; Fernandez-Banet J; Pavlicek A; Wong KK; Christensen JG; Olson P
    Mol Cancer Ther; 2021 Jun; 20(6):975-985. PubMed ID: 33722854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in
    Adeegbe DO; Liu S; Hattersley MM; Bowden M; Zhou CW; Li S; Vlahos R; Grondine M; Dolgalev I; Ivanova EV; Quinn MM; Gao P; Hammerman PS; Bradner JE; Diehl JA; Rustgi AK; Bass AJ; Tsirigos A; Freeman GJ; Chen H; Wong KK
    Cancer Immunol Res; 2018 Oct; 6(10):1234-1245. PubMed ID: 30087114
    [No Abstract]   [Full Text] [Related]  

  • 34. IRF8 deficiency-induced myeloid-derived suppressor cell promote immune evasion in lung adenocarcinoma.
    Gao Z; Liu S; Xiao H; Li M; Ren WG; Xu L; Peng ZM
    J Transl Med; 2024 Jul; 22(1):678. PubMed ID: 39049031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes.
    Singh A; Daemen A; Nickles D; Jeon SM; Foreman O; Sudini K; Gnad F; Lajoie S; Gour N; Mitzner W; Chatterjee S; Choi EJ; Ravishankar B; Rappaport A; Patil N; McCleland M; Johnson L; Acquaah-Mensah G; Gabrielson E; Biswal S; Hatzivassiliou G
    Clin Cancer Res; 2021 Feb; 27(3):877-888. PubMed ID: 33077574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo miRNA knockout screening identifies miR-190b as a novel tumor suppressor.
    Hong H; Yao S; Zhang Y; Ye Y; Li C; Hu L; Sun Y; Huang HY; Ji H
    PLoS Genet; 2020 Nov; 16(11):e1009168. PubMed ID: 33137086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.
    Budczies J; Romanovsky E; Kirchner M; Neumann O; Blasi M; Schnorbach J; Shah R; Bozorgmehr F; Savai R; Stiewe T; Peters S; Schirmacher P; Thomas M; Kazdal D; Christopoulos P; Stenzinger A
    Br J Cancer; 2024 Aug; 131(3):524-533. PubMed ID: 38866964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.
    Zheng H; Zhao W; Yan C; Watson CC; Massengill M; Xie M; Massengill C; Noyes DR; Martinez GV; Afzal R; Chen Z; Ren X; Antonia SJ; Haura EB; Ruffell B; Beg AA
    Clin Cancer Res; 2016 Aug; 22(16):4119-32. PubMed ID: 26964571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinoma.
    Lee K; Cha H; Kim J; Jang Y; Son Y; Joe CY; Kim J; Kim J; Lee SH; Lee S
    Sci Rep; 2024 Sep; 14(1):21096. PubMed ID: 39256604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy.
    Zhang C; Yin K; Liu SY; Yan LX; Su J; Wu YL; Zhang XC; Zhong WZ; Yang XN
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.